Consensus DNA motifs recognized by BCL6
The Zn fingers of BCL6 binds to DNA and recognizes specific DNA motifs: the M00424 motif, a consensus sequence for the NKX-homeobox family of transcription factors, the M2 motif, which mimics an M00424 half site; and the M0 motif (see details in .
BCL6 cellular function -BCL6 cellular function in germinal centers of lymph nodes follicles
Mature naïve B cells migrate from the bone marrow to lymphoid nodes, meet the antigen, they are stimulated to proliferate and further differentiate into centroblasts in germinal centers (GC) of lymphoid follicles. There, cells are subjects to somatic hypermutation and class switch recombination, to further differenciate into memory B cells or plasma cells. This process also requires the presence of follicular helper T cells. BCL6 has a major role in this process. In particular, BCL6 prevents ATM and TP53 (Phan et al., 2004) to induce apoptosis in response to DNA rearrangements such as those necessary for somatic hypermutation and class switch recombination processes.
BCL6 is therefore essential for normal B cell development (reviews in Albagli-Curiel, 2003; Jardin et al., 2007; Parekh et al., 2008; Basso and DallaFavera, 2010; Pellicano and Holyoake, 2011; Wagner et al., 2011; Okada et al., 2012 ).
-T follicular helper cells BCL6 is essential for the development of follicular helper T (Tfh) cells. Tfh cells are defined by the expression of the surface markers CXCR5 and PD-1 and synthesis of IL4 and IL21. BCL6 upregulation of B cells in the outer follicle sustains their interactions with helper T cells and allows them to enter the germinal centers (GC) region (Poholek et al., 2010; Kitano et al., 2011; Baumjohann et al., 2011) . ICOS induces BCL6, and BCL6 then induces CXCR5. Tfh cells were lost in the absence of B cells, demonstrating a B cell requirement for maintenance of BCL6 and Tfh cell commitment (Choi et al., 2011) . BCL6 and MAF cooperate to induce Tfh cell differentiation (Kroenke et al., 2012) .
-Other tissues BCL6 promotes survival of olfactory sensory neurons (Otaki etal., 2010) . BCL6 associate to NACC1 in brain regions (Korutla et al., 2009 ). BCL6 forms a complex with BCOR on the promoters of Notch target genes in Xenopus embryos (Sakano et al., 2010) . BCL6-overexpression inhibits osteoclastogenesis, and the PRDM1 (Blimp-1)/BCL6 balance is essential in regulating the bone homeostasis by controlling osteoclastogenesis (Miyauchi et al., 2010) . BCL6 controls the expression of the CC-type chemokine genes and attenuates allergic airway inflammation in pulmonary epithelium (Seto et al. 2011) . BCL6 repression activity BCL6 binds to DNA as a homodimer and recruits corepressor molecules, which, in turn, recruit class I and II histone deacetylases. BCL6 and histone deacetylases (HDACs) form stable complexes. BCL6 binds HDACs both directly through its C-terminal Zn fingers and through its N-terminal BTB/POZ domain and indirectly by recruiting several co-repressors such as BCOR, NCOR1, NCOR2 (which bind in a mutually exclusive way to the BTB/POZ domain), CTBP1 (which binds the BTB/POZ and the PEST domains), and MTA3 (which binds the PEST domain). Deacetylation of histones leads to transcriptional repression of BCL6 targets. BCL6 interacts with ZBTB17 to repress CDKN1A and BCL2 (Phan et al., 2005) . BCL6 has also been found to interact with other POK family members ((POZ and Krüppel)/ZBTB (zing finger and BTB) protein family) such as ZBTB7A (LRF) and ZBTB16 (PLZF).
BCL6 targets
An integrated biochemical and computational approach has recently identified thousands of BCL6 direct target genes, including B cell receptor (BCR; note: nothing to do with BCR, the partner of ABL1) and CD40 signaling genes (involved in signal transduction, MAPK activation, NF-AT activation, and NF-kB activation); T cell-mediated B-cell activation; apoptosis (BCL2, proteins involved in positive and negative regulation of the DISC complex and caspase activation, suggesting a role for BCL6 in balancing pro-and antiapoptotic programs in GC B cells); response to DNA damage (ATM, TP53, CDKN1A, ATR, CHEK1, TP53BP1...); interferon and cytokine signaling (interferon-type and interleukin receptors that lead to activation of JAK/STAT. STAT1, STAT3, and STAT5A were also found to be directly repressed by BCL6); Toll-like receptor signaling; TGFb receptor signaling; and WNT signaling .
BCL6 regulation -B cell receptor
B cell receptor (BCR) induces BCL6 phosphorylation by MAPK1 on Ser333 and Ser343, which targets BCL-6 for rapid degradation by the ubiquitin/proteasome pathway (Niu et al., 1998) . FBXO11 promotes BCL6 ubiquitylation and degradation (Duan et al., 2012) . -DNA damage After DNA damage, the kinase ATM promotes BCL6 phosphorylation; follows an interaction with PIN1 required for BCL6 degradation (Phan et al., 2007) . -EP300 EP300 binds and acetylates BCL6, which inactivates BCL6 (acetylation disrupts the ability of BCL6 to recruit histone deacetylases). The same two pathways (HDAC pathway and SIRT2 pathway) that regulate acetylation-mediated activation of TP53 also control acetylation-mediated inactivation of BCL6 (Bereshchenko et al., 2002) . BCL6 represses the expression of EP300 and its cofactor BAT3 (Cerchietti et al., 2010) . EP300 acetylates and activates PAX5 (He et al., 2011) , which enhances BCL6. -Autoregulation BCL6 protein binds BCL6 gene promoter, and repress BCL6, mechanism of negative autoregulation (Pasqualucci et al., 2003) . PATZ1 interacts with BCL6 and is required for its negative autoregulation (Pero et al., 2012) . -CD40 signaling CD40 signaling activates various pathways, including NF-kB, NF-AT, and AP-1 (Francis et al., 1995) . ILF2 (NF45) and ILF3 (NF90) form the nuclear factor of activated T-cells (NF-AT), a crucial transcription factor essential for productive T cell activation (Kao et al., 1994) . CD40 signalling reduces BCL6 expression, through induction of IRF4 by the NF-kB pathway (Saito et al., 2007) . -PRDM1 (review in Crotty et al., 2010) JUND/AP-1 and activated STATs drive high BCL6 expression in GC B cells (Arguni et al., 2006) . STAT5 up-regulates BCL6 expression (Scheeren et al., 2005) ; in contrast, STAT3 up-regulates PRDM1 (Diehl et al., 2008) (the protein coded from PRDM1 is named Blimp-1). BCL6 directly promotes the expression of BACH2, which repress PRDM1 (Blimp-1). BCL6 also suppresses PRDM1 (Blimp-1) through repression of IRF4. IRF4 binds to and induces PRDM1. PRDM1 (Blimp-1) abrogates BCL6. PAX5 (protein name: BSAP) contributes to BCL6 expression (Nera et al., 2006; Tarlinton, 2011) . PAX5 abrogates PRDM1 (Blimp-1), which abrogates PAX5. BCL6 and PAX5 promote the expression of AICDA and UNG (which have a major role in somatic hypermutation and classswitch recombination) (Alinikula et al., 2011) . BCL6 positively regulates AICDA, IRF8, and MYB via repression of MIR155 , 2006) . It is also to be noted that IRF4 is involved in the t(6;14)(p25;q32) IRF4/IGH. PRDM1 (Blimp-1) is inactivated in about 50% of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (ABC-DLBCL) (Mandelbaum et al., 2010) .
Homology

BTB/POZ -Zinc Finger proteins (PLZF, HIC1, KUP, BAZF, ttk (drosophila), BrC (drosophila)...).
Mutations
Note Chromosomal translocations involving BCL6 are found in 40% of diffuse large B-cell lymphomas (DLBCL), 5-10% of follicular lymphomas (FL), and 50% of nodular lymphocyte predominant Hodgkin lymphomas. Mutations in the autoregulatory region of BCL6 leads to a constitutive BCL6 expression (Pasqualucci et al., 2003) . IRF4 response elements in the BCL6 gene mediate repression of BCL6. Mutations in the IRF4 repression region of BCL6 gene also leads to constitutive expression of BCL6 (Saito et al., 2007) . MYC, BCL2, and BCL6 rearrangements were detected in 6%, 15%, and 29% respectively of diffuse large Bcell lymphoma (DLBCL) patients. Double or triple rearrangements were detected in 3% of these patients. MYC rearrangement was associated with a significantly worse overall survival. BCL6 rearrangement also predicted a significantly shorter overall survival, especially for the non-GC phenotype (Akyurek et al., 2012) .
Implicated in 3q27 rearrangements /NHL (non Hodgkin lymphomas)
Disease B cell non-Hodgkin Lymphoma (B-NHL) Prognosis Generally considered to be a better prognosis if there is increased expression of BCL6. The mechanism by which its expression is increased does not seem to matter (ie different translocation partners increasing its expression results in the same prognosis). Cytogenetics 3q27 rearrangements/aberrations are diverse and include:
translocations, micro-deletions, point mutations and hypermutation. Approximately 50% of 3q27 translocations involves Ig genes at 14q32 (IgH), 2p12 (IgK) and 22q12 (IgL) (e.g. t(3;14)(q27;q32)). Less than half (~40%) include a variety of other chromosomal regions (1q21, 2q21, 4p11, 5q31, 6p21, 7p12, 8q24, 9p13, 11q13, 11q23, 12q11, 13q14-21, 14q11, 15q21; 16p11...). In addition, there are frequent bi-allelic alterations (translocation and deletion or mutation on the nontranslocated allele). Hybrid/Mutated gene hybrid gene and transcripts are formed following promoter substitution between BCL6 and its different partners. Chimeric transcripts are generally detected containing the 5' part of the gene partner fused to the normal BCL6 exon 2 splice acceptor site. In some cases reciprocal chimeric transcripts driven by the 5' regulatory region of BCL6 fused to the partner gene coding region, have been characterised.
-t(1;3)(q25;q27) the gene in 1q25 is GAS5 -t(2;3)(p12;q27) the gene in 2p12 is IGK -t(3;3)(q25;q27) the gene in 3q25 is MBNL1 -t(3;3)(q27;q27) the gene in 3q27 is ST6GAL1 -t(3;3)(q27;q27) the gene in 3q27 is EIF4A2 -t(3;3)(q27;q29) the gene in 3q29 is TFRC -t(3;4)(q27;p13) the gene in 4p13 is RHOH -t(3;6)(q27;p22) the gene in 6p22 is HIST1H4I -t(3;6)(q27;p21) the gene in 6p21 is PIM1 -t(3;6)(q27;p21) the gene in 6p21 is SFRS3 -t(3;6)(q27;q15) the gene in 6q15 is SNHG5 -t(3;7)(q27;p12) the gene in 7p12 is IKZF1 -t(3;7)(q27;q32) the gene in 7q32 is FRA7H -t(3;8)(q27;q24.1) the gene in 8q24.1 is MYC -t(3;9)(q27;p24) the gene in 9p24 is DMRT1 -t(3;9)(q27;p11) the gene in 9p11 is GRHPR -t(3;11)(q27;q23) the gene in 11q23 is POU2AF1 -t(3;12)(q27;p13) the gene in 12p13 is GAPDH -t(3;12)(q27;q12) the gene in 12q12 is LRMP -t(3;13)(q27;q14) the gene in 13q14 is LCP1 -t(3;14)(q27;q32) the gene in 14q32 is IGH -t(3;14)(q27;q32) the gene in 14q32 is HSP90AA1 -t(3;16)(q27;p13) the gene in 16p13 is CIITA -t(3;16)(q27;p11) the gene in 16p11 is IL21R -t(3;19)(q27;q13) the gene in 19q13 is NAPA -t(3;22)(q27;q11) the gene in 22q11 is IGL Abnormal protein No fusion protein.
t(9;22)(q34;q11) leukemias
Disease BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition (Duy et al. 2011) . In chronic myelogenous leukemia (CML), BCL6 acts as a critical effector downstream of FoxO in selfrenewal signaling of CML-initiating cells. Therefore, pharmacological inhibition of BCL6 may represent a novel strategy to eradicate leukemia-initiating cells in CML .
Breast cancer
Disease BCL6 protein is elevated in human breast cancers, especially in high-grade, poorly differentiated and metastatic breast cancer cases (Bos et al., 2003; Logarajah et al., 2003; Brill et al., 2010) . PRL (prolactin) rapidly suppressed BCL6. Loss of PRLSTAT5a signaling and concomitant upregulation of BCL6 may represent a regulatory switch facilitating undifferentiated histology and poor prognosis (Brill et al., 2010) .
Bladder transitional cell carcinoma
Disease BCL6 protein overexpression is observed in half of the cases of transitional cell carcinoma. However, BCL6 over-expression has a negative correlation with the histological grade (Cho et al., 2007) .
Soft tissue tumors
Disease BCL6 expression is more frequent in malignant compared with benign/uncertain solitary fibrous tumors, as well as in leiomyosarcomas compared with leiomyomas (Walters et al., 2011) .
Neuroblastoma
Disease
In the neuroblastic phenotype of neuroblastoma, BCL6 expression is associated with increased time to relapse and increased overall survival (Chamdin et al., 2009 ).
Gastric cancer
Disease
In a study of 100 gastric cancer cases, BCL6 was highly expressed in differentiated cancers and reduced or absent in undifferentiated cancers. However, survival was identical in BCL6-positive and BCL6-negative cases (Hirata et al., 2009 ).
Multiple myeloma
Disease IL6 induces transcriptional up-regulation of BCL6 via JAK/STAT3 pathway. TNF (TNF alpha) up-regulates BCL6. BCL6 expression is mediated independantly via both JAK/STAT3 and NF-KB pathways in multiple myeloma cells (Hideshima et al., 2010) .
Breakpoints
Note Clustered in a 3,3 kb EcoRI fragment (MTC) includind exon 1A and intron 1.
